Thymosin Alpha-1 is the first amino acid 1 to 28 of prothymosin alpha, a protein derived from the thymus gland. It was first isolated and characterised by Allan Goldstein at George Washington University in 1977 and has been commercially available as the pharmaceutical Zadaxin, produced by SciClone Pharmaceuticals, since 1985. It is approved as a medicine in over 35 countries for hepatitis B, hepatitis C, and as an adjunct to cancer chemotherapy and immune-compromised states. Its mechanism is well-characterised: it activates dendritic cells and T-lymphocytes, enhances natural killer cell activity, and stimulates production of interferons and interleukins involved in antiviral and antitumour immunity.
Clinical Evidence
The most extensive clinical evidence for Thymosin Alpha-1 is in chronic viral hepatitis. Multiple randomised controlled trials, summarised in a Cochrane systematic review, found that Thymosin Alpha-1 significantly improved viral clearance rates in hepatitis B compared to placebo, with a favourable safety profile. In hepatitis C, Thymosin Alpha-1 combined with interferon improved sustained viral response rates. In cancer settings, Thymosin Alpha-1 has been studied as an adjunct to chemotherapy and radiotherapy, with evidence for improved immune reconstitution, reduced infection rates, and potentially improved treatment tolerability.
Age-Related Immune Decline
Thymic involution, the progressive replacement of thymic tissue with fat that begins in puberty and accelerates from middle age, reduces the output of naive T cells that are essential for responding to novel pathogens and cancer cells. This immune ageing, called immunosenescence, is a primary driver of increased susceptibility to infections and cancer in older adults, and of the reduced vaccine responsiveness that makes influenza and COVID-19 vaccination less effective in the elderly. Thymosin Alpha-1 has been studied for its ability to partially compensate for thymic involution by activating the remaining T cell pool and enhancing dendritic cell function.
COVID-19 and Acute Infections
During the COVID-19 pandemic, Thymosin Alpha-1 attracted significant attention in China and Italy, where case series and small trials suggested that its early administration in hospitalised patients with severe COVID-19 reduced mortality compared to standard care. A multi-centre trial published in Clinical Infectious Diseases found significant reductions in 28-day mortality in severe COVID-19 patients treated with Thymosin Alpha-1 compared to control. The mechanism proposed is attenuation of the cytokine storm that drives severe COVID-19 pathology by modulating excessive immune activation while maintaining antiviral T cell function.
Practical Considerations
Thymosin Alpha-1 is a licensed pharmaceutical in many jurisdictions but requires prescription in the UK for medicinal use. It is administered subcutaneously. Standard protocols in research settings use 1.6mg twice weekly for acute applications. For immune support in ageing populations, lower-dose maintenance protocols have been studied. Its safety profile is excellent: thousands of patients treated in clinical trials have shown no significant serious adverse effects attributable to the compound. Anyone in the UK wishing to access Thymosin Alpha-1 should do so through a private prescriber who can provide pharmaceutical-grade, licensed product and appropriate clinical monitoring.